Polycystic ovarian syndrome (PCOS) is an obvious indication for long-term treatment. Combined oral contraceptives (COC) remain the first choice for the treatment of hyperandrogenism in most patients. However, differences in endocrine and metabolic parameters between obese and lean patients have been postulated. This is the first study evaluating the effect of COC treatment in obese versus non-obese PCOS patients. In total, 28 lean [body mass index (BMI) <25 kg/m 2 )] and 15 obese (BMI >30 kg/m 2 ) women patients were enrolled in the study. The concentrations of androgens, sex hormone-binding globulin (SHBG) and lipids were measured before and after 6 months of treatment with COC containing low-androgenic progestins. Clinical androgenic symptoms were monitored. There was a lower concentration of SHBG in obese patients, but there were no differences in androgen concentrations between both groups before the study. Highly significant changes in concentrations of testosterone (P < 0.001), androstenedione (P < 0.0001), SHBG (P < 0.001) and LH (P ⍧ 0.01) were demonstrated in lean patients, with only less significant changes in SHBG (P < 0.01) and testosterone (P < 0.05) in obese patients during the study. Clinical androgenic symptoms improved significantly (P ⍧ 0.05) only in the group of lean women. No reduction in lowdensity lipoprotein-cholesterol/high-density lipoprotein-cholesterol ratio was observed in either group. In conclusion, the positive effect of COC treatment on androgen production, serum androgen binding capacity, and clinical androgenic symptoms was negatively influenced by an increased BMI.
Introduction
metabolic disturbances. One of the most important factors determining the phenotype of the disease is the presence or Polycystic ovarian syndrome (PCOS) is an evident indication absence of obesity. Approximately 50% of women suffering for long-term treatment as a proven risk factor for non-insulinfrom PCOS are obese (Yen, 1980) . Obesity itself negatively dependent diabetes mellitus (NIDDM) and coronary artery influences the synthesis of sex hormone-binding globulin disease (Dahlgren et al., 1992; Ehrmann et al., 1999; Legro (SHBG) , androgen production, and insulin sensitivity (Kurtz et al., 1999; Cibula et al., 2000) . Moreover, improvement of et al., 1987; Pasquali and Casimirri, 1993) . Higher concentraskin androgenic symptoms also requires long-term medication.
tions of androgens and more pronounced insulin resistance Combined oral contraceptives (COC) remain the first choice were demonstrated in obese PCOS women compared with lean for the treatment of hyperandrogenism, as a key endocrine patients Acién et al., 1999 ; Ciampelli disturbance, for most women with PCOS. COC have been et al., 1999) . The increased concentrations of androgens and shown to inhibit significantly the ovarian androgens production insulin stimulate the synthesis of insulin-like growth factor-I and to increase serum androgen binding capacity (Falsetti and (IGF-I) and suppress SHBG and insulin-like growth factor Galbignani, 1990; Dahlgren et al., 1998; Gjonnaess, 1999) .
binding protein-1 (IGFBP-1) production in the liver (Buyalos An effect on adrenal steroidogenesis has also been proposed et Morales et al., 1996) . As a result, higher amounts (Wild et al., 1991) . In consequence, treatment with COC of free, non-bound forms of insulin and IGF-I might influence significantly reduces serum concentrations of both total and ovarian steroidogenesis in obese PCOS patients. free androgens.
Other than the documented differences in endocrine and PCOS is a heterogeneous syndrome in that it presents with a broad spectrum of clinical manifestations and endocrine or metabolic parameters in obese and lean patients, little is known 
Materials and methods
Germany). LDL-cholesterol was calculated according to using the Friedewald formula (LDL-cholesterol ϭ total cholesterol -HDLPatients cholesterol -triglycerides/2.19 mmol/l) (Friedewald et al., 1972) . Overall, 46 women with PCOS were enrolled in the study. PCOS
The reference values for normal concentrations were as follows: was defined as follows: (i) oligomenorrhoea (menstrual cycle longer testosterone 0.5-2.63 nmol/l, androstenedione 1.57-5.4 nmol/l, DHEA than 35 days) from menarche; (ii) increased concentrations of at 0.8-10.5 nmol/l, DHEAS 2.4-14.5 µmol/l and SHBG 43.2-96.0 nmol/l. least one androgen; and (iii) clinical manifestations of hyperandrogenism (acne, hirsutism, or both). Only lean patients with a Statistical analysis BMI Ͻ25 kg/m 2 and obese patients with a BMI Ͼ30 kg/m 2 were selected. All women were aged over 18 years, had not used Due to skewed distribution of the data, the sign test and Wilcoxon's robust paired test were used for the evaluation of intra-individual hormonal therapy or systemic treatment of acne for the preceding 6 months, and were not using any long-term medication. Women differences. Student's t-test after transformation of original variables to minimum skewness and the Mann-Whitney robust test in the presenting with a secondary endocrine disorder, such as non-classic congenital adrenal hyperplasia, hyperprolactinaemia or thyroid dysnon-transformed variables were used for the evaluation of differences between subjects with BMI Ͻ25 kg/m 2 and those with BMI function, those wishing to conceive within the next 6 months, those with contraindications to COC use, or with a blood pressure Ͼ30 kg/m 2 . For the evaluation of the pre/post-treatment differences in the two groups with different BMI, the sign test and Wilcoxon's Ͼ140/90 mmHg were excluded from the study. Altogether, three women withdrew from the study (intolerance of COC treatment in paired test were used. two cases, personal reasons in one case). A total of 28 lean and 15 obese women completed the study protocol. All participants were studied before and after 6 months of therapy with monophasic (Table I) . However, there were no significant
The weight and height of all women were taken to calculate the BMI. differences in lipid profile in the concentrations of androgens, Waist and hip circumference were measured in the standing position at the levels of the umbilicus and spina iliaca anterior superior to or in the severity of clinical symptoms between lean and obese calculate the waist-to-hip ratio (WHR). Blood pressure readings PCOS women before the treatment.
were taken twice in the sitting position after a 10 min rest. Increased
The significance of changes in monitored parameters during body hair was graded using a previously described method (Ferriman the study in both groups is demonstrated in Table II. In the and Gallwey, 1961); hirsutism was defined as a Ferriman-Gallwey group of lean women, highly significant changes in circulating score Ͼ8. Acne severity was graded in three locations (face, back, concentrations of testosterone (P Ͻ 0.001), androstenedione and chest) using a modification of a published technique (Burke (P Ͻ 0.0001), LH (P Ͻ 0.001) and SHBG (P Ͻ 0.01) were and Cunliffe, 1984) . The value of total grade was analysed in this observed. Obese patients showed a less pronounced yet study. Blood was collected from all women during the early follicular significant increase in SHBG concentrations (P Ͻ 0.01), supphase, i.e. between days 3 and 6 of the menstrual cycle. Blood was pression of testosterone production of borderline significance (P centrifuged and frozen at -20°C. Provided that spontaneous menstrual Ͻ 0.05), and non-significant changes in androstenedione and bleeding failed to occur until day 45 of the cycle, bleeding was induced by progesterone administration. A shortened adrenocorticotrophic LH concentrations. The acne score (P Ͻ 0.05) and the severity hormone (ACTH) test was performed to exclude non-classic conof increased body hair (P ϭ 0.05) were significantly improved genital adrenal hyperplasia (NCCAH).
in lean women only. The concentration of total cholesterol increased significantly (P Ͻ 0.05) during the treatment in both The BMI exceeds the limit for obesity in about 50% of FSH and testosterone were determined by chemiluminescent assay using an ACS:180 autoanalyser (Bayer Diagnostics GmbH, Munich, PCOS patients. An increased BMI impairs many endocrine DHEA ϭ dehydroepiandrosterone; DHEA-S ϭ DHEA sulphate; FAI ϭ free androgen index; F-G ϭ Ferriman-Gallwey; HDL ϭ high-density lipoprotein; LDL ϭ low-density lipoprotein; NS ϭ not significant; SHBG ϭ sex hormone binding globulin; TG ϭ triglycerides.
and metabolic parameters. First, obesity significantly influ- Conway et al., 1989) , but not confirmed by others (Golland et al., 1990; Graf et al., 1990) . Recently, a negative effect of ences circulating concentrations of SHBG. BMI is inversely correlated with SHBG in healthy women (Glass et al., 1981;  obesity on plasma concentrations of testosterone and SHBG in PCOS patients was reported (Ciampelli et al., 1999) . Purifoy et al., 1981; Pasquali et al., 1987) , as well as in women with PCOS Graf et al., 1990) . These findings were supported by Acién et al. who found a correlation between BMI and testosterone concentrations Conflicting results have been reported in terms of a correlation between BMI and androgen production. Significantly (Acién et al., 1999) . Moreover, the presence of obesity has a major impact on increased production rates of androstenedione and DHEA were demonstrated in obese non-PCOS women versus normalthe lipid profile and insulin metabolism. PCOS and obesity exert a synergistic deleterious effect on glucose tolerance weight women (Kirschner et al., 1983; Kurtz et al., 1987) . Higher concentrations of androgens in obese PCOS patients and insulin sensitivity (Ciampelli et al., 1999) . Many studies have demonstrated a more atherogenic lipid profile in obese were documented by several authors (Dunaif et al., 1988;  PCOS patients (Falsetti and Pasinetti, 1995) . Furthermore, a in androgen production between lean and obese women before treatment, highly significant changes in androgen concentrapositive relationship between BMI and plasminogen activator inhibitor-1 (PAI-1) activity and a negative relationship between tions were demonstrated in lean women, but only a minor positive effect of the treatment in obese patients. The most BMI and IGFBP-1 were found in PCOS women (Morales et al., 1996; Atiomo et al., 2000) . marked difference in treatment outcome between the two groups was found in androstenedione, with lean women As a result, obesity is one of the main factors determining the phenotype of the disease. There are many pathogenic showing a highly significant decline in serum concentrations whereas circulating concentrations were not significantly mechanisms which could adversely influence the treatment of obese PCOS women. However, little is known about the altered in obese women. SHBG production likewise was increased in a more pronounced fashion in lean women. influence of BMI on the effect of different treatment modalities. One exception documented a significantly worsened response
The different effect of treatment on androgen production is consistent with a different clinical outcome. The acne score by obese PCOS women undergoing ovarian electrocautery (Gjonnaess, 1994) . and the grade of increased body hair growth improved significantly only in non-obese subjects. This study appears to be the first evaluating a different response by PCOS patients to COC on the basis of their Surprisingly, no beneficial effect of COC treatment on lipid profile was observed. The slightly increased concentraobesity. Oral contraceptives are a therapeutic modality which addresses many of the endocrine disturbances associated with tions of total cholesterol in both groups, like the raised LDLcholesterol concentrations in lean women, are consistent with PCOS. The treatment corrects androgen overproduction by several mechanisms, including gonadotrophin suppression, published data (Petersen et al., 1988; Kuhl et al., 1990) . However, an increase in HDL-cholesterol, reportedly associated stimulation of the androgen binding capacity, and suppression of ovarian and adrenal androgen synthesis. Reducing the with new progestin-containing agents by healthy users and PCOS women alike (Peterson et al., 1988 ; Gevers Leuven concentrations of free and total androgens during COC treatment of PCOS patients has been demonstrated in many et al., 1990) , was not demonstrated in either of the patient groups. studies (Falsetti and Pasinetti, 1990; Dahlgren et al., 1998; Gjonnaess, 1999) .
The finding in the current study of an adverse effect of obesity on treatment outcome underlines the need for an Agents containing norgestimate, desogestrel, and gestodene were used in the current study. All of the above gestagens are individualized approach to long-term treatment of PCOS women. The optimal treatment modality in obese women classified into the same group of what is referred to as low-androgenic progestins or 'new progestins' (Speroff and seems to be weight reduction, where the effect on androgen production and insulin sensitivity has been well demonstrated DeCherney, 1993; Collins, 1994) . The minimal androgenicity of these progestins is reflected in significant increases in SHBG (Pasquali et al., 1989; Andersen et al., 1995; Holte et al., 1995) . However, other possibilities should be considered for concentrations in users of combined COC (Bergink et al., 1981; Hammond et al., 1984; Palatsi et al., 1984; van der Vange, the future, such as a combination of COC with insulin-receptor sensitizers. Future studies are warranted to evaluate the efficacy et al ., 1990) . A consequence of decreased concentrations of free androgens and minimal affinity of new progestins alone of these combinations in obese women. to the androgenic receptor is a beneficial effect of COC on skin androgenic symptoms (Mango et al., 1996; Lucky et al., 
